Navigation Links
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Date:2/6/2012

879.42 Myeloma 7899.43 Nasopharyngeal Cancer 7929.44 Neuroendocrine Cancer (general) 7939.45 Neuroendocrine Cancer (pancreatic) 7949.46 Neurofibromatosis 7969.47 non-Hodgkin's Lymphoma 7979.48 Non-Small Cell Lung Cancer 7999.49 Oesophageal Cancer 8059.50 Oral Cancer 8079.51 Osteo Sarcoma 8089.52 Ovarian Cancer 8099.53 Pancreatic Cancer 8139.54 Peritoneal Cancer 8169.55 Prostate Cancer 8189.56 Radio/chemotherapy-induced Alopecia 8229.57 Radio/chemotherapy-induced Infection 8229.58 Renal Cancer 8239.59 Sarcoma (general) 8289.60 Small Cell Lung Cancer 8309.61 Soft Tissue Sarcoma 8339.62 Solid Tumor 8359.63 Squamous Cell Cancer 8399.64 Synovial Sarcoma 8409.65 T-cell Lymphoma 8419.66 Testicular Cancer 8429.67 Thyroid Cancer 8439.68 Unspecified 8459.69 Vaccine adjunct 8489.70 Waldenstrom's hypergammaglobulinemia 84810 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator 84910.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 85310.2 Company Facts and Ranking 85510.3 Competitive Fall-Out Assessment 86110.4 Abbott 86410.5 Acceleron Pharma 87510.6 Access 87910.7 Active Biotech 88310.8 Adherex 88710.9 Advantagene 89510.10 Advaxis 90110.11 Advenchen 90510.12 Aeterna Zentaris 90910.13 Agennix 91610.14 Aida Pharmaceuticals 92010.15 Alnylam 92410.16 Ambit Biosciences 92810.17 Ambrilia Biopharma 93410.18 Amgen 93810.19 Amphora 94610.20 Angiogen 95010.21 Angiogenex 95410.22 Angstrom Pharmaceuticals 95810.23 Ansaris 96210.24 Antisoma 96610.25 Arana Therapeutics 97010.26 Ariad 97410.27 Arno Therapeutics 98410.28 ArQule 98810.29 Array BioPharma 99410.30 Astellas 99810.31 Astex Therapeutics 100410.32 AstraZeneca 100810.33 Attenuon 101610.34 Austrianova 102210.35 Bayer 102610.36 BioAlliance Pharma 103610.37 BioAxone 104110.38 Biocad 104510.39 Boehringer Ingelheim 105110.40 Bolder BioTechnology 105710.41 Bristol-Myers Squibb 106310.42 BTG 107510.43 Cancer Research Technology 108110.44
'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Reportlinker Adds Personalized Medicine 2010: Assessing the Opportunities and Challenges in Commercializing Companion Diagnostics and Targeted Therapies
2. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
3. KellBenx Secures Exclusive Worldwide License With AdnaGen for Commercializing Patented Antibodies
4. Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
5. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
6. Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
7. Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis
8. Efficacy Data from Phase III VELOUR Trial in Colorectal Cancer to be Presented at Angiogenesis Foundations 2011 M. Judah Folkman International Conference in Cambridge, Mass.
9. Triple Analysis: Prostate Cancer, Angiogenesis and Peptides
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... Executive Officer of the company, effective December 22, 2014. ... "The Board of Directors of ConvaTec thanks Mr. Berger ... three years," said Magnus Lundberg , the Chairman ... the company is well positioned for the future."  The ...
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
(Date:12/22/2014)... 22, 2014  Pfenex Inc. (NYSE MKT: PFNX) today ... has been filed and is now open and that ... Department of Health and Human Services (HHS), through the ... "We are extremely pleased to have the IND now ... a significant milestone in our company,s partnership with BARDA ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3
(Date:12/25/2014)... When head lice hits a home or school, ... get rid of it while keeping it from taking over ... have the solution right in their neighborhood: Lice Troopers ... provides full spectrum head lice screening and treatment services to ... Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... the Court is scheduled to convene a Joint Status ... 2015, at 10:00 a.m. Parties have been directed to ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Each year ... and 2 million hospital admissions across the nation (according ... ). The CDC’s National Hospital Ambulatory Medical Care ... a survey conducted in 2010. They estimated that there ... that resulted in a primary diagnosis of broken bone ...
(Date:12/24/2014)... 25, 2014 Epigenetics finds applications in ... including oncology, drug discovery, developmental biology, and research for ... one of the most widely used techniques for the ... the prevalence of cancer is rapidly growing worldwide. In ... million cancer deaths, and 32.6 million people living with ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3
... 12 million people in the United States are cancer survivors. ... annually than the care of people who have never had ... are treated for and survive cancer are susceptible to later ... per year. People are considered cancer survivors from the moment ...
... Multiple Sclerosis sufferers emotional support through group therapy sessions ... NHS almost 500 per patient, a study at The ... planning a larger multi-centre study into the issue to ... MS services currently provided by the NHS. The ...
... identify patients who will benefit from a potentially toxic second ... of cure in select patients with head and neck cancer. ... of the American Cancer Society, the findings could help guide ... Radiation is often used to treat patients with head and ...
... the brain activity of teens, recorded while they are listening ... songs. "We have scientifically demonstrated that you can, to ... predict cultural popularity," says Gregory Berns, a neuroeconomist and director ... Consumer Psychology is publishing the results of the study, ...
... June 10 (HealthDay News) -- The debate over whether or not ... study finds a small risk among people who are heavy cell ... Dr. Otis Brawley, chief medical officer of the American Cancer ... "the study is not conclusive that cell phones cause brain tumors." ...
... , SATURDAY, June 11 (HealthDay News) -- Baseline concussion ... some cases, an expert warns. Baseline concussion testing provides ... reaction time, working memory and attention span. Athletes who suffer ... large decrease in the score, they are typically banned from ...
Cached Medicine News:Health News:Cancer survivors spend more on health care 2Health News:Group therapy helps MS sufferers cope with depression, study finds 2Health News:Group therapy helps MS sufferers cope with depression, study finds 3Health News:Certain head and neck cancer patients benefit from second round of treatment 2Health News:Teen brain data may predict pop song success, Emory study finds 2Health News:Teen brain data may predict pop song success, Emory study finds 3Health News:Heavy Cell Phone Use Might Raise Risk of Brain Tumors 2Health News:Heavy Cell Phone Use Might Raise Risk of Brain Tumors 3Health News:Validity of Baseline Concussion Tests Questioned 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: